AbbVie Inc. is a global biopharmaceutical company dedicated to developing advanced therapies that address some of the world's most complex health challenges. With a mission to improve patient outcomes through innovative treatments, AbbVie focuses on areas such as immunology, oncology, neuroscience, and virology. The company's strategy emphasizes research and development, leveraging cutting-edge science and technology to create breakthrough medications. AbbVie operates through a robust pipeline of products, including established therapies and new drug candidates, aiming to enhance the quality of life for patients worldwide while driving sustainable growth.

ABBVIE INC

AbbVie (NYSE: ABBV) continues to be a strong pick for income investors, highlighted by its impressive record of 52 consecutive years of dividend increases, earning the title of Dividend King. As of now, AbbVie offers a forward yield of 3.43%. Concerns regarding the loss of patent exclusivity for its blockbuster...

AbbVie Emerges as a Top Income Investment Despite Humira Patent Loss Concerns, Driven by Strong Sales from Skyrizi and Rinvoq

AbbVie continues to shine as a Dividend King, boasting 52 years of consecutive increases and a forward yield of 3.43%. With strong sales from Skyrizi and Rinvoq alleviating concerns over Humira's patent loss, can AbbVie maintain its momentum in an evolving market?